Pressure BioSciences (OTCQB: PBIO), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumables and specialty-testing services to the worldwide pharmaceuticals, biotherapeutics, nutraceuticals, cosmeceuticals, agrochemical, food & beverage, cannabis and other industries, has announced a partnership with Crème de Canna (“CdC”). According to the announcement, the two companies have entered a commercial agreement for the supply and distribution of PBIO’s UltraShear(TM)-processed nanoemulsified CBD in a nano-CBD topical spray, allowing it to be purchased outside of California for the first time ever. “CdC’s founding partners were among the earliest innovators in California’s emerging cannabis industry,” said Pressure BioSciences chair Jeffrey N. Peterson in the press release.
“Their relentless focus on controlling quality from plant selection and growth through to product design, manufacture and finished products has distinguished and equipped them for survival and success through the tumultuous history of this industry. Since its formal founding in 2010, Crème de Canna has been recognized as the oldest ‘social equity’ licensed manufacturer and distributor of cannabis products in California. In addition to their web-based marketing and distribution capabilities in California and beyond, they have recently partnered with Catalyst, a leading chain of California dispensaries, providing CdC with a new, highly respected, and successful sales channel. . . . CdC’s history, principles and performance made them an attractive partner for our early efforts in developing and testing UST-processed nanoemulsified THC oral spray products in California. Their team has worked closely with us to produce small batches of Nano-THC Oral Spray for consumer focus group testing, with notable success reported in several previous PBIO press releases. Upon PBIO’s recent development and release of a Nano-CBD Topical Spray with our first few distribution partners, it was an obvious next step for the CdC team to partner with us to seize the opportunity to lead as a California-based distribution partner.”
To view the full press release, visit https://ibn.fm/jCXIx
About Pressure BioSciences Inc.
Pressure BioSciences is a global leader in providing innovative, broadly enabling, high-pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical and agrochemical, as well as food and beverage manufacturing. The company’s products utilize both constant and alternating pressure. Its patented enabling technology platform — Pressure Cycling Technology (“PCT”) — uses alternating cycles of pressure to control biomolecular interactions, such as cell lysis and biomolecule extraction, safely and reproducibly. PCT-based products are beginning to be widely used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counterbioterrorism applications. PBIO has recently expanded its market opportunities with the acquisition of the BaroFold(TM) patented technology platform, allowing the company to enter the biopharma contract services and GMP manufacturing equipment sector. The company has also developed the scalable and high-efficiency pressure-based UltraShear Technology platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room-temperature-stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. The company’s commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to its customers. For more information, visit the company website at www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork
